A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

Novartis

Status and phase

Completed

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Vildagliptin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00351546

CLAF237A2352

Details and patient eligibility

About

Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vildagliptin on insulin sensitivity in people with type 2 diabetes.

Enrollment

12 patients

Sex

All

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed with type 2 diabetes at least 3 months prior to screening
Blood glucose criteria must be met
On stable dose of metformin therapy
BMI less than or equal to 39

Exclusion criteria

Type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes
Treatment with thiazolidinediones or use of insulin within the previous 3 months
Significant illness within 2 weeks prior to dosing
High fasting triglycerides as defined by the protocol

Other protocol-defined inclusion/exclusion criteria may apply